Ventripoint Diagnostics (TSXV: VPT) is evidently looking to grow its portfolio of intellectual property. The company this morning announced that it has filed for a provisional patent in the United States for its novel cardiac measurement approach.
The IP being protected reportedly tracks the movement of the heart and valves through the entire heartbeat, whereas traditionally measurements have focused on the full and empty points within the cardiac cycle. The new technique reportedly provides cardiologists additional and more price data about the function of the heart through this motion tracking.
The development reportedly is an extension of the firms current artificial intelligence platform. Currently, the platform focuses on the reliable and accurate volumetric measurements of the heart and its four chambers.
“Since Ventripoint’s VMS+3.0 system produces a mathematical model of the entire heart throughout the cardiac cycle, we are able to create novel measurements to characterize the function of the whole heart. This is now becoming even more important with the myriad of effects of COVID-19 on the heart.”
Dr George Adams, Executive Chairman of Ventripoint
Ventripoint Diagnostics last traded at $0.62 on the TSX Venture.
FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
